Fierce Pharma

JANUARY 2, 2024

On the heels of a major Paxlovid inventory write-off in the United States, many more doses of Pfizer's COVID-fighting antiviral are going to waste overseas. | At the end of November, more than 1.5 million courses of Pfizer’s Paxlovid had expired unused in European countries, analysts at Airfinity said in a new report. The total tally of expired doses in Europe is expected to hit 3.1 million by the end of next month, representing a value of $2.2 billion.

352

352

Medical Sales Guru

JANUARY 2, 2024

The role of a medical sales representative involves navigating intricate dynamics with healthcare professionals. These professionals hold significant authority in determining a salesperson’s access and the fate of a product. Consequently, many representatives opt to play it safe , fearing potential alienation that might hinder future sales opportunities.

Medical 130

Medical Medical sales Sales Healthcare 130

Fierce Pharma

JANUARY 2, 2024

AbbVie is entering 2024 with a foothold in the antibody-drug conjugate (ADC) field thanks to its late-2023 buyout of ImmunoGen worth more than $10 billion. | According to a recent securities filing, AbbVie only entered the ImmunoGen bidding war after other buyout interest led the ADC specialist to widen its pool of potential purchasers. When it came down to the final three players, AbbVie's offer blew the others out of the water.

266

266

MedCity News

JANUARY 2, 2024

A recent Deloitte report found that improving health equity is a top-10 goal for 83% of life sciences and healthcare C-suite executives in 2024. The report also laid out factors that will likely influence health equity in 2024, including AI.

Healthcare 128

Healthcare Healthcare 128

Advertisement

Distribution

Fierce Pharma

JANUARY 2, 2024

AstraZeneca and Sanofi have scored first in | AstraZeneca and Sanofi have scored first in China with an approval for their respiratory syncytial virus (RSV) immunization Beyfortus for infants, with the companies expecting the shot to be available there for the 2024-25 season. Beyfortus is the only immunization approved for babies entering their first RSV season to protect them against lower respiratory tract infection.

216

216

MedCity News

JANUARY 2, 2024

Longboard Pharmaceuticals’ epilepsy drug candidate bexicaserin met the main efficacy goal of its Phase 1b/2a study along with safety data suggesting a potential edge over current treatments. With Longboard now preparing to advance to Phase 3 testing, its stock price soared more than 300%.

Safety 122

Safety Pharma Pharmaceutical Biopharma 122

MedCity News

JANUARY 2, 2024

Yet another study has been published showing that patients receiving care at PE-owned hospitals experienced a higher rate of hospital-acquired adverse events, like infections and falls, than patients receiving care at hospitals that are not PE-owned. The research comes as concerns about PE-owned hospitals are intensifying — from leaders both within and outside of the healthcare industry.

Patients 115

Patients Leads Healthcare Healthcare 115

PharmExec

JANUARY 2, 2024

Companies must address myriad challenges to improve upon issues such as data quality and transparency, process efficiency, and artificial intelligence/machine learning preparedness.

98

98

MedCity News

JANUARY 2, 2024

The biggest trend in gene therapy development is the potential of several treatments for rare neurological diseases to move from the bench to the bedside.

Biopharma 122

Biopharma 122

Pharmaceutical Commerce

JANUARY 2, 2024

Agreement includes novel cell therapy for hematology that has the opportunity to bring a potential best-in-class treatment to patients with blood cancers.

Patients 105

Patients 105

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

MedCity News

JANUARY 2, 2024

Novartis is paying Voyager Therapeutics $100 million up front to collaborate on gene therapies for Huntington’s disease and spinal muscular atrophy. The deal builds on a relationship the companies started in 2022.

Biopharma 112

Biopharma Pharma 112

European Pharmaceutical Review

JANUARY 2, 2024

A paper published in the European Journal of Pharmaceutics and Biopharmaceutics has reviewed the current application status of Quality by Design (QbD) within the framework of the ICH guidelines (ICH Q8(R2) – Q14 and ICH Q2(R2)). Over the past several years, the pharmaceutical industry has faced challenges regarding quality assurance in drug development, the author asserted.

Pharmaceutical products 97

Pharmaceutical products Pharmaceutical Manufacturing Marketing 97

MedCity News

JANUARY 2, 2024

A recent Oliver Wyman report laid out five Affordable Care Act trends to watch, including the rise of ICHRAs and the need for a “seamless member experience.

112

112

pharmaphorum

JANUARY 2, 2024

Verona Pharma has agreed a new $400 million debt facility with Oxford Finance and Hercules Capital designed to help the company navigate the possible approval and launch of ensifentrine, its therapy for chronic obstructive pulmonary disease (COPD). The Anglo-US company has already tapped $50 million of the funding and can take another $100 million if an ongoing review of ensifentrine by the US FDA results in regulatory approval.

Marketing 97

Marketing FDA Pharma 97

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

PharmaTech

JANUARY 2, 2024

Reviewing regulatory documents, such as 483 forms and Warning Letters, can aid in determining a facility’s inspection readiness, says Siegfried Schmitt, vice president, Technical at Parexel.

92

92

European Pharmaceutical Review

JANUARY 2, 2024

For an upfront price of $1.0 billion, AstraZeneca has agreed to acquire Gracell Biotechnologies, supporting the development of cell therapies in haematology and autoimmune diseases. Gracell’s FasTCAR-enabled B-cell maturation antigen (BCMA)/CD19 dual-targeting autologous CAR-T cell therapy GC012F, is an asset AstraZeneca will gain access to as part of the new acquisition agreement announced on 26 December 2023.

Manufacturing 81

Manufacturing Marketing Engineering Pharma 81

PharmExec

JANUARY 2, 2024

Merger agreement includes the Gracell FasTCAR platform, which could significantly improve the efficacy of CAR T-cell therapies.

98

98

European Pharmaceutical Review

JANUARY 2, 2024

According to results from a survey by GlobalData, the top challenges for the pharmaceutical industry in 2024 will be inflation, geopolitical conflict and drug pricing pressures. Data outcomes revealed that most respondents from Pharma considered that drug pricing and reimbursement constraints will have a negative impact in 2024. Inflation and geopolitical pressure The second biggest negative impact was thought to be geopolitical conflicts and inflation.

Pharma 80

Pharma Medicine Government Marketing 80

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety

Healthcare Success

JANUARY 2, 2024

We hope your holiday season was filled with good cheer and plenty of new business opportunities. Now that the holidays have drawn to a close, it’s time to return to your 2024 marketing plan and make adjustments that ensure your business is taking advantage of the latest trends in healthcare marketing to reach patients and HCPs more effectively and make a lasting impression.

Healthcare 77

Healthcare Healthcare Marketing Healthcare Provider 77

pharmaphorum

JANUARY 2, 2024

Novo Nordisk is planning to open an AI research facility in London, UK, as part of a drive to place the technology at the heart of its drug discovery operations

79

79

PharmaTech

JANUARY 2, 2024

Buffers, stabilizers, and cryoprotectants play major roles in cell therapy formulations.

94

94

pharmaphorum

JANUARY 2, 2024

Astellas has licensed up to four macrophage enhancer drugs with potential as cancer immunotherapies from Elpiscience in a $1.

89

89

Advertisement

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

Specialization

PharmaTech

JANUARY 2, 2024

Analytical methods and tools play a pivotal role in cleaning validation.

98

98

pharmaphorum

JANUARY 2, 2024

Shares in US biotech Anavex Life Sciences fell sharply this morning after Rett syndrome candidate Anavex 2-73 failed a phase 2/3 trial

77

77

PharmaTimes

JANUARY 2, 2024

The programme is the only remote, digital delivery nursing home training programme for dementia

Training 87

Training Patients 87

pharmaphorum

JANUARY 2, 2024

Novartis has doubled down on its gene therapy collaboration with Voyager Therapeutics, licensing candidates for Huntington's disease and SMA

73

73

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Leads

Contrarian Sales Techniques

JANUARY 2, 2024

Embarking on a new month in the sales world is like setting off on an exciting journey, with each phase offering its own unique challenges and opportunities. Let's map out the monthly routine of a sales superstar, broken down into early, mid, and end-of-month rituals. This isn't just about hitting targets. It's about creating a rhythm that keeps our sales champ at the top of their game.

Sales 59

Sales Prospecting Product Knowledge Training 59

Pharmaceutical Technology

JANUARY 2, 2024

The age-related macular degeneration (AMD) market is expected to grow at a compound annual growth rate of 14.1% throughout the forecast period (2021-2031), reaching $27.5bn across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) according to GlobalData’s report: Age-Related Macular Degeneration: Seven-Market Drug Forecast and Market Analysis - Update.

Marketing 59

Marketing 59

pharmaphorum

JANUARY 2, 2024

AstraZeneca and Sanofi’s long-acting antibody Beyfortus has been approved in China for the prevention of respiratory syncytial virus (RSV) infections in newborns and infants

57

57

PharmaTimes

JANUARY 2, 2024

The number of people getting tested over the last decade has increased by 133%

87

87

Advertisement

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

Management